Edition:
United Kingdom

Nektar Therapeutics (NKTR.OQ)

NKTR.OQ on NASDAQ Stock Exchange Global Select Market

52.85USD
22 Jun 2018
Change (% chg)

$-3.01 (-5.39%)
Prev Close
$55.86
Open
$56.10
Day's High
$56.19
Day's Low
$52.84
Volume
10,279,920
Avg. Vol
1,511,519
52-wk High
$111.36
52-wk Low
$17.52

Latest Key Developments (Source: Significant Developments)

Nektar Therapeutics Submits NDA To Treat Chronic Low Back Pain
Thursday, 31 May 2018 

May 31 (Reuters) - Nektar Therapeutics ::NEKTAR THERAPEUTICS ANNOUNCES SUBMISSION OF A NEW DRUG APPLICATION TO THE U.S. FDA FOR NKTR-181, A FIRST-IN-CLASS INVESTIGATIONAL OPIOID TO TREAT CHRONIC LOW BACK PAIN IN ADULT PATIENTS NEW TO OPIOID THERAPY.  Full Article

Syndax And Nektar Therapeutics Announce Immuno-Oncology Clinical Trial Collaboration
Wednesday, 30 May 2018 

May 30 (Reuters) - Nektar Therapeutics ::SYNDAX AND NEKTAR THERAPEUTICS ANNOUNCE IMMUNO-ONCOLOGY CLINICAL TRIAL COLLABORATION.NEKTAR- ANNOUNCED NON-EXCLUSIVE, CLINICAL COLLABORATION TO EVALUATE SAFETY, EFFICACY OF NEKTAR'S NKTR-214, IN COMBINATION WITH SYNDAX'S ENTINOSTAT.NEKTAR THERAPEUTICS - COLLABORATION WILL EVALUATE COMBINATION OF ENTINOSTAT WITH NKTR-214 IN PATIENTS WITH PD-1 REFRACTORY MELANOMA.NEKTAR THERAPEUTICS - ADDITIONAL FINANCIAL DETAILS AND OTHER TERMS OF AGREEMENT WERE NOT DISCLOSED.  Full Article

Nektar Therapeutics Reports Q1 Loss Per Share $0.60
Thursday, 10 May 2018 

May 10 (Reuters) - Nektar Therapeutics ::REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2018.Q1 LOSS PER SHARE $0.60.Q1 REVENUE $38 MILLION VERSUS I/B/E/S VIEW $35.6 MILLION.Q1 EARNINGS PER SHARE VIEW $-0.54 -- THOMSON REUTERS I/B/E/S.  Full Article

Nektar And Takeda To Evaluate Combination Of NKTR-214, A CD122-Biased Agonist, And Tak-659, In Liquid And Solid Tumors
Tuesday, 24 Apr 2018 

April 24 (Reuters) - Nektar Therapeutics ::NEW ONCOLOGY CLINICAL COLLABORATION BETWEEN NEKTAR AND TAKEDA TO EVALUATE COMBINATION OF NKTR-214, A CD122-BIASED AGONIST, AND TAK-659, A DUAL SYK AND FLT-3 INHIBITOR, IN LIQUID AND SOLID TUMORS.NEKTAR THERAPEUTICS - NEKTAR AND TAKEDA WILL EACH MAINTAIN GLOBAL COMMERCIAL RIGHTS TO THEIR RESPECTIVE INVESTIGATIONAL MEDICINES.NEKTAR THERAPEUTICS - NEKTAR AND TAKEDA WILL SPLIT COSTS RELATED TO CLINICAL TRIAL.NEKTAR THERAPEUTICS - FIRST TRIAL IS EXPECTED TO START IN SECOND HALF OF 2018.NEKTAR - FIRST TRIAL TO EVALUATE COMBINATION OF EVERY 3-WEEK SCHEDULE OF NKTR-214 WITH ORAL DAILY DOSES OF TAK-659 IN PATIENTS WITH NON-HODGKIN LYMPHOMA.  Full Article

Nektar Therapeutics Says Received Notice Of Termination From Bayer Of Co-Development, License, Co-Promotion Agreement
Friday, 15 Dec 2017 

Dec 15 (Reuters) - Nektar Therapeutics ::NEKTAR THERAPEUTICS - ‍ON DEC 14, CO RECEIVED NOTICE OF TERMINATION FROM BAYER OF CO-DEVELOPMENT, LICENSE,CO-PROMOTION AGREEMENT, DATED AUG 1, 2007​.  Full Article

Nektar Therapeutics Says Received Notice Of Termination From Daiichi Of Collaboration Agreement
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Nektar Therapeutics ::NEKTAR THERAPEUTICS - ON DEC 6, CO RECEIVED NOTICE OF TERMINATION FROM DAIICHI OF COLLABORATION AGREEMENT WHICH WILL BECOME EFFECTIVE AS OF FEB 4, 2018.NEKTAR THERAPEUTICS - CO WILL PAY TO DAIICHI A $12.5 MILLION TERMINATION PAYMENT AND ALL RIGHTS AND LICENSES GRANTED TO DAIICHI UNDER AGREEMENT.NEKTAR THERAPEUTICS - TERMINATION PAYMENT DOES NOT CHANGE CO'S S 2017 FINANCIAL GUIDANCE, WHICH WAS PROVIDED IN FINANCIAL RESULTS ON NOV 7.  Full Article

Nektar Therapeutics estimates wind down costs of $3 mln to $4 mln related to ceasing clinical program
Friday, 24 Nov 2017 

Nov 24 (Reuters) - Nektar Therapeutics :Nektar Therapeutics says estimates that it will incur about $3 million to $4 million of wind-down costs.Nektar Therapeutics - costs related to concluding co’s activities related to Bayer's phase 3 Amikacin Inhale clinical program under 2007 agreement.Nektar Therapeutics - based on discussion with Bayer, Nektar does not expect Bayer to move forward any further with the Amikacin Inhale program.  Full Article

EMA recommends against approval after re-examination of Nektar's drug onzeald
Friday, 10 Nov 2017 

Nov 10 (Reuters) - EU Medicines Agency::EU MEDICINES AGENCY RECOMMENDS AGAINST APPROVAL AFTER RE-EXAMINATION OF NEKTAR'S DRUG ONZEALD FOR TREATMENT OF BREAST CANCER WHICH HAS SPREAD TO BRAIN‍​.  Full Article

Nektar Therapeutics reports Q3 earnings per share $0.39
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Nektar Therapeutics ::Nektar Therapeutics reports financial results for the third quarter of 2017.Q3 earnings per share $0.39.Q3 revenue $152.9 million versus $36.3 million.Q3 revenue view $114.6 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $0.17 -- Thomson Reuters I/B/E/S.  Full Article

Bristol-Myers Squibb and Nektar Therapeutics announce Oncology clinical collaboration
Tuesday, 27 Sep 2016 

Bristol-myers Squibb Co : Myers Squibb and Nektar Therapeutics announce Oncology clinical collaboration to evaluate combination of Opdivo (nivolumab) and NKTR-214 . Says Bristol-Myers Squibb and Nektar will equally share costs of combined therapy trials . Myers Squibb co - an initial dose-escalation trial is underway with Opdivo and NKTR-214 . Nektar will maintain its global commercial rights to NKTR-214 .Myers Squibb and Nektar Therapeutics announce Oncology clinical collaboration to evaluate combination of Opdivo (nivolumab) and NKTR-214.  Full Article

Tech, healthcare to get bumped up in Russell index remake

NEW YORK, June 21 Largecap technology and healthcare sectors are expected to see a bump in weighting when index provider FTSE Russell completes its annual refresh of its benchmarks on Friday, as investors brace for what is annually the largest stock trading day of the year.